April 24, 2024
Oropharyngeal Candidiasis

Oropharyngeal Candidiasis Market is witnessed high growth due to increasing prevalence of HIV globally

Oropharyngeal candidiasis, also known as oral or oropharyngeal thrush, is a common opportunistic oral infection caused by a yeast (fungus) called Candida albicans. It typically presents as white or yellowish patches that can be wiped off the tongue or inside of the mouth. The infection commonly occurs in people with weakened immune systems such as those suffering from HIV/AIDS, diabetes and those undergoing cancer treatment or taking antibiotics. The global oropharyngeal candidiasis market is expected to gain considerable traction over the forecast period owing to increasing prevalence of HIV globally.

The Global Oropharyngeal Candidiasis Market is estimated to be valued at US$ 456 MN in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024 to 2031.

Key Takeaways
Key players operating in The Global Oropharyngeal Candidiasis Market are Bayer AG, Teva Pharmaceuticals, Stellar Pharma, Pfizer, Wockhardt, Ranbaxy Laboratories, Bristol Laboratories, Glenmark Pharmaceuticals Ltd, and GlaxoSmithKline. Growing incidences of HIV/AIDS across various parts of the world represents key opportunities for players in the market. With higher prevalence of the disease in developing parts of Asia Pacific and Africa, manufacturers are focusing on expanding their presence in these untapped markets.

Market drivers
The increasing prevalence of diabetes and HIV globally is the major market driver. According to UNAIDS, around 38 million people were suffering from HIV globally in 2019. Moreover, the number of people suffering from diabetes has more than quadrupled since 1980, rising from 108 million to 422 million adults. Rising availability of generics and over-the-counter drugs are expected to boost the market growth during the forecast period by making treatment more affordable.

PEST Analysis
Political: Government policies pertaining to healthcare access in different countries and regions determine the adoption of oropharyngeal candidiasis treatment drugs. Stringencies or relaxations in regulatory approvals also impact market dynamics.

Economic: Growth prospects of this market are directly related to economic conditions of regions and local markets. Higher disposable incomes boost healthcare spending on such specialized drugs and treatments.

Social: Changing lifestyles and demographic trends affecting disease prevalence. Urbanization and increasing stressful modern lifestyles contribute to higher incidences of oral candidiasis globally.

Technological: Advancements in drug delivery mechanisms, formulations aid better efficacy and patient compliance. Biologics and novel antifungal compounds in clinical trials can expand treatment options if approved.

Geographical regions where market in terms of value is concentrated

North America leads in terms of oropharyngeal candidiasis treatment market value currently, owing to developed healthcare systems and higher accessibility in countries like the US and Canada. Europe is another major revenue generator, driven by growing aging populations and greater health awareness. Parts of Asia Pacific witness rising disease burdens coupled with improving medical technologies adoption.

The fastest growing region for the given market

Asia Pacific region is poised to showcase fastest growth in the global oropharyngeal candidiasis market over the forecast period. Factors such as expanding patient pools, increasing health expenditure, growing medical tourism, rapidly developing economies and their strengthening healthcare infrastructure render the region highly lucrative. Moreover, heightened awareness about various oral diseases and their management aids market expansion across APAC.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it